EAC 2019 Update in Allergy, Asthma and Immunology
The EAC 2019 Update in Allergy, Asthma & Immunology meeting will provide learners with knowledge regarding novel disease state developments and the expanding therapeutic armamentarium in the field of allergy, asthma and immunology. Learners will not only gain insights with regard to selecting the best therapeutic alternative for each patient, but they will also have the opportunity to develop novel strategies designed to enhance therapeutic adherence through shared decision making. The format will incorporate problem based learning (PBL), uniquely designed to interface with lectures in context to the core issues relevant to the cases. By means of active discussion, learners will be challenged to formulate and justify medical decision making concerning advancements in the diagnosis and treatment strategies for patients. Topics of discussion will include updates in diagnosis and treatment of HAE, biologics for severe asthma, allergic skin diseases, advances in peanut allergy treatments and management of penicillin and other antibiotic allergies.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.”
Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 15.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Target Audience
Practicing allergists
Allied health professionals
Learning Objectives
Upon completion of this activity, participants should be able to:
--Describe the burden of illness attributable to allergic diseases.
--Define severe asthma and describe the major phenotypes
--Outline an approach to the use of biologics for allergic diseases
--Discuss therapeutic options for the management of peanut allergy
--Discuss advancements in the diagnosis and treatment of HAE
--Outline strategies to improve allergy immunotherapy efficacy and minimize adverse reactions
This activity is supported by independent educational grants from CSL Behring, DBV Technologies, Optinose, Pharming, Shire and Stallergenes Greer.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and Eastern Allergy Conference (EAC). The American College of Allergy, Asthma and Immunology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation
The American College of Allergy, Asthma & Immunology designates this live activity for a maximum of 15.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 15.50 AMA PRA Category 1 Credit™
- 15.50 Attendance